GB cancer is: Uncommon, so few studies done prospectively. Looking at results in people treated empirically, perhaps one person in 10 will respond. That needs to be balanced against side effects that tend to occur in most. Frank discussion about symptom rrelief focus rather than "shrink tumor" at all cost.
Answered 9/22/2013
4.9k views
It is worth a trial: Being a rare cancer, we have limited data about efficacy of chemotherapy. Yet many phase 2 studies have been done which predictably show that gemcitabine is an active drug and benefits about1/3 patients. More recently combination chemotherapy using Cisplatin with gemcitabine , for the first time, showed a superior efficacy with 2 drugs over one . You have nothing to lose yet may buy 6 to 12 months.
Answered 6/24/2014
4.9k views
A doctor has provided 1 answer
A doctor has provided 1 answer
4 doctors weighed in across 2 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question